DMAC

Business Context and Reporting Period

Company: DiaMedica Therapeutics Inc. (DMAC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2025
Business Overview: DiaMedica is a clinical-stage biopharmaceutical company developing DM199, a recombinant form of human tissue kallikrein-1 (KLK1), for the treatment of preeclampsia (PE) and acute ischemic stroke (AIS). The company has no commercial product revenue and relies on equity financing and interest income.

Key Financial Metrics

Debt and Liquidity: The company has no long-term debt obligations other than minimal finance and operating lease liabilities. Total current liabilities were $4.7 million. Management expects current cash resources to fund operations for at least the next 12 months.

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses rose to $8.1 million in Q1 2025 from $5.7 million in Q1 2024.
  • R&D Expenses: Increased to $5.7 million (from $3.7 million) due to the continuation and global expansion of the ReMEDy2 clinical trial, increased manufacturing development, and clinical team expansion.
  • G&A Expenses: Increased to $2.5 million (from $2.1 million), primarily driven by additional non-cash share-based compensation related to a retiring Board member's stock option extension.
• Decreased Interest Income: Other income, net, declined to $0.4 million (from $0.6 million) due to lower average marketable securities balances.
• Cash Position: Combined cash and marketable securities decreased by approximately $6.8 million from the prior quarter, reflecting the burn rate of clinical operations.

Guidance, Outlook, and Risks

Clinical Program Updates:

• Preeclampsia (PE): A Phase 2 investigator-sponsored study is ongoing in South Africa. Part 1A preliminary topline results are expected between late June and early July 2025.
• Acute Ischemic Stroke (AIS): The Phase 2/3 ReMEDy2 trial is experiencing slower-than-expected site activations and enrollment. Contributing factors include hospital staffing shortages, protocol logistics, and competition for subjects. The company has expanded its internal clinical team and brought trial management in-house to mitigate these delays.

Outlook and Capital Needs:

• Management anticipates moderate increases in quarterly expenses as clinical trials expand globally.
• The company expects to incur significant operating losses for the foreseeable future and will require substantial additional capital to complete development and seek regulatory approval.
• Future funding may be sought through equity or debt financings, strategic collaborations, or licensing agreements.

Risks and Contingencies:

• Legal Proceedings: An ongoing appeal regarding a dispute with ICON/PRA Netherlands over clinical study data ownership and damages. A consolidated ruling is expected around June 20, 2025.
• Regulatory Risks: Potential impacts from changes in FDA funding and staffing levels could delay reviews.
• Financial Risk: If adequate funding is not available, the company may need to scale back operations, delay trials, or seek strategic partnerships on unfavorable terms.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $37.3 million cash balance against the projected burn rate of ~$7.1 million per quarter to confirm the 12-month liquidity assertion.
• ReMEDy2 Trial Enrollment: Monitor upcoming disclosures regarding the success of mitigation strategies for site activation and enrollment delays in the AIS trial.
• PE Trial Results: Track the release of Part 1A topline results for the preeclampsia study expected in mid-2025.
• Legal Resolution: Review the outcome of the consolidated appeal against ICON/PRA Netherlands expected in June 2025.
• Capital Markets: Assess the company's ability to raise additional capital given the current market environment for clinical-stage biotechs.